The latest price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) was reported by Canaccord Genuity on July 17, 2026. The analyst firm set a price target for $290.00 expecting JAZZ to rise to within 12 months (a possible 17.04% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) was provided by Canaccord Genuity, and Jazz Pharmaceuticals initiated their buy rating.

The last upgrade for Jazz Pharmaceuticals PLC happened on May 19, 2026 when UBS raised their price target to $307. UBS previously had a neutral for Jazz Pharmaceuticals PLC.

The last downgrade for Jazz Pharmaceuticals PLC happened on November 24, 2025 when UBS changed their price target from $163 to $188 for Jazz Pharmaceuticals PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on July 17, 2026 so you should expect the next rating to be made available sometime around July 17, 2027.

While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a initiated with a price target of $0.00 to $290.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $247.77, which is within the analyst’s predicted range.